Astrazeneca (AZN) Total Debt (2009 - 2026)

Astrazeneca (AZN) has reported Total Debt for 18 consecutive years, with -$24.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Debt rose 8.38% year-over-year to -$24.5 billion; the TTM figure through Mar 2026 stood at -$24.5 billion (up 8.38% YoY), while the FY2025 annual figure was -$21.6 billion, down 174.93% from the prior year.
• Total Debt came in at -$24.5 billion for Q1 2026 at Astrazeneca, down from -$21.6 billion in the prior quarter.
• The five-year high for Total Debt was $28.8 billion in Q4 2024, with the low at -$28.9 billion in Q3 2024.
• Average Total Debt over 5 years is -$16.0 billion, with a median of -$24.7 billion recorded in 2025.
• Across the five-year window, Total Debt gained 18.41% in 2022 and slumped 174.93% in 2025, its largest moves.
• Year by year, Total Debt stood at $28.3 billion in 2022, then slipped by 2.78% to $27.5 billion in 2023, then gained by 4.91% to $28.8 billion in 2024, then sank by 174.93% to -$21.6 billion in 2025, then retreated by 13.16% to -$24.5 billion in 2026.
• According to Business Quant data, Total Debt over the past three periods registered -$24.5 billion, -$21.6 billion, and -$24.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.